inMIND: A Phase 3 Study of Tafasitamab plus Lenalidomide Add-On to Rituximab vs Placebo plus Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

被引：0

作者：

Sehn, Laurie H. ^{[1
,2
]}

Scholz, Christian W. ^{[3
]}

Luminari, Stefano ^{[4
]}

Salar, Antonio ^{[5
]}

Wahlin, Bjorn E. ^{[6
]}

Gopal, Ajay K. ^{[7
]}

Bonnet, Christophe ^{[8
]}

Trneny, Marek ^{[9
]}

Paneesha, Shankara ^{[10
]}

Manzke, Oliver ^{[11
]}

Seguy, Francis ^{[11
]}

Li, Di ^{[12
]}

Huebel, Kai ^{[13
]}

机构：

[1] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Vivantes Klinikum Urban, Dept Hematol & Oncol, Berlin, Germany

[4] Azienda USL IRCCS Reggio Emilia, Hematol Unit, Reggio Emilia, Italy

[5] Hosp Mar IMIM, Dept Haematol, Barcelona, Spain

[6] Karolinska Inst, Dept Med, Hematol Unit, Stockholm, Sweden

[7] Univ Washington Med, Div Med Oncol, Seattle, WA USA

[8] Univ Liege, Ctr Hosp Univ, Clin Hematol, Liege, Belgium

[9] Charles Univ Prague, Gen Hosp, Fac Med 1, Dept Med 1, Prague, Czech Republic

[10] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[11] Incyte Biosci Int Sarl, Morges, Switzerland

[12] Incyte Corp, Wilmington, DE USA

[13] Univ Hosp Cologne, Dept Internal Med Oncol & Hematol, Cologne, Germany

来源：

关键词：

IBCL; non-Hodgkin lymphoma; follicular lymphoma; marginal zone lymphoma; tafasitamab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-131

引用

页码：S402 / S402

页数：1